Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC

NovoCure Ltd

Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).
In ICI subgroup, median OS 18.5 vs 10.8 months (HR 0.63, p=0.03); in docetaxel 11.1 vs 8.7 months (HR 0.81, p=0.28).
No added systemic toxicities; most common device effect was grade 1-2 dermatitis (43%).
Company plans to submit for regulatory approval; first-line NSCLC studies underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.